Experts discuss the promising future of HER2-targeted therapies, highlighting new treatments and combination strategies for ...

Senate Democrats are advancing a new prescription drug pricing agenda they say would lower costs for patients, reduce wasteful health care spending, and strengthen US biomedical innovation, while ...

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

An independent predictor of CS-responsive MG was ptosis (OR, 2.13; 95% CI, 1.05-4.32), but this association only remained when AChR antibody–positive status was an independent predictor of CRMG (OR, 2 ...

The Consolidated Appropriations Act of 2026 features new language that could change the way that pharmacy benefit managers (PBMs) operate in the US.

Medicare beneficiaries whose physicians participate in accountable care organizations (ACOs), particularly those taking on financial risk for cost and quality, receive substantially more primary and ...

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges ...

Margaret Krackeler, MD, of Kaiser Permanente Northern California, discusses the growing role of real-world treatment data in CLL and other cancers.

Objective: To address concerns about payment adequacy in Medicare Advantage (MA) plans, a 2017 federal policy change increased risk scores and associated capitated payments for community-dwelling ...

Experts discuss the potential of TKIs like zongertinib and seviberatinib as first-line treatments for HER2-mutant non-small cell lung cancer.

Nurse navigators play a crucial role in managing HER2-targeted therapy side effects, ensuring patient education and early toxicity detection.

Experts discuss the challenges of integrating new cancer therapies, addressing multidisciplinary care, evolving guidelines, and the financial burden on patients.